News Novo partners with Hims & Hers again, ending GLP-1 spat Novo Nordisk and Hims & Hers have set their differences aside, agreeing to work together once again on the sale of GLP-1 agonists.
News FDA ramps up its pushback against compounded GLP-1s In a move that will please Novo Nordisk and Eli Lilly, the FDA sent warnings to 30 telehealth firms, accusing them of illegally marketing GLP-1 drugs.
News Novo Nordisk plans €432m investment in Irish GLP-1 plant Novo Nordisk invests in an Irish plant as it prepares for regulatory approvals of its Wegovy pill outside the US.
News Lilly says orforglipron tops Novo pill in diabetes trial Lilly's head-to-head trial of oral GLP-1 orforglipron and Novo Nordisk's oral semaglutide in type 2 diabetes raises as many questions as it answers.
News Novo Nordisk beefs up in oral obesity drugs with Vivtex deal Novo Nordisk is leaving no stone unturned in its bid to maintain its position in weight-loss therapies as it signs a $2.1bn alliance with Vivtex.
News Novo Nordisk to cut GLP-1 prices in tough US market Novo Nordisk has turned to pricing as a means to shore up its position in the increasingly competitive market for GLP-1 agonist therapies in the US.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
